骨髓增殖性肿瘤与妊娠:概述与实践建议
该综述聚焦骨髓增殖性肿瘤(MPN)合并妊娠的胎儿与母体挑战,现有文献多涉及原发性血小板增多症(ET),真性红细胞增多症(PV)和骨髓纤维化较少。ET活产率约70%,孕早期胎儿丢失约30%为主要并发症;PV妊娠相关并发症风险更高,需更积极治疗。作者评估文献并结合自身经验提出管理建议。
要点
- ET妊娠活产率约70%,孕早期胎儿丢失约30%为主要并发症。
- PV妊娠并发症风险更高,需更积极治疗并严格控血细胞比容<45%。
- 高危及部分低危ET/PV有复发性胎儿丢失等可予干扰素α降细胞治疗。
核心结论
- MPN合并妊娠需按风险分层管理,PV并发症风险高于ET,需更积极干预。
研究设计与样本
- 综述类:评估MPN与妊娠相关文献并结合作者自身经验提出管理建议。
主要发现
- ET活产率估计约70%,孕早期胎儿丢失约30%为主要并发症。
- PV妊娠相关并发症风险更高,需更积极治疗。
- 阿司匹林可能降低胎儿丢失风险,但全身抗凝或降细胞治疗的附加获益在高危疾病外不明确。
关键数值与推荐
- 推荐所有高危及部分低危ET/PV患者(有复发性胎儿丢失、明显脾大或放血后血细胞比容控制欠佳)使用干扰素α降细胞治疗。
- 所有PV女性应通过放血维持血细胞比容严格<45%。
- 有静脉血栓史者建议低分子量肝素全身抗凝。
临床怎么用
- PV妊娠应严格放血控血细胞比容<45%,有静脉血栓史者用低分子量肝素抗凝。
- 高危及部分低危ET/PV有复发性胎儿丢失等可予干扰素α降细胞治疗。
局限性
- 现有文献多涉及ET,PV和骨髓纤维化数据较少。
- 阿司匹林以外全身抗凝或降细胞治疗的附加获益在高危疾病外不明确。
- 需前瞻性临床试验实施风险适应治疗干预进一步明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pregnancy in the context of myeloproliferative neoplasms (MPN) poses unique fetal and maternal challenges. Current literature in this regard mostly involves essential thrombocythemia (ET) and less so polycythemia vera (PV) or myelofibrosis. In ET, live birth rate is estimated at 70% with first trimester fetal loss (˜ 30%) as the major complication. Risk of pregnancy-associated complications is higher in PV, thus mandating a more aggressive treatment approach. Herein, we appraise the relevant literature, share our own experience and propose management recommendations. Aspirin therapy may offer protection against fetal loss; however the additive benefit of systemic anticoagulation or cytoreductive therapy, in the absence of high risk disease, is unclear. We recommend cytoreductive therapy in the form of interferon alpha in all high risk and select low-risk ET and PV patients with history of recurrent fetal loss, prominent splenomegaly or suboptimal hematocrit control with phlebotomy. In addition, all women with PV should maintain strict hematocrit control <45% with the aid of phlebotomy. Systemic anticoagulation with low molecular weight heparin is advised in patients with history of venous thrombosis. Further clarification awaits prospective clinical trials that implement risk adapted therapeutic interventions.
引用
- Gangat N, Tefferi A. Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations. Am J Hematol. 2020. PMID: 33296529. doi:10.1002/ajh.26067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。